Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
SCP-cisplatin
- Development stage
- Preclinical
- Lead developer
- Nexus Alliance Biopharmaceuticals
- Modality
- Small Molecules, Biodegradable Polymers → Polymer-based Nanoparticles → Nanoparticles → Drug Delivery Systems
- Administration
- Intravenous
01
Overview
SCP-Cisplatin is a preclinical-stage antineoplastic agent developed by Nexus Alliance Biopharmaceuticals, specifically targeting cervical cancer. This candidate utilizes the company's proprietary Self-Correcting Polymer (SCP) technology to formulate cisplatin, a well-established platinum-based chemotherapeutic. The SCP platform is designed to enhance the pharmacokinetic profile and therapeutic index of cisplatin by improving solubility, prolonging circulation time, and potentially reducing systemic toxicities such as nephrotoxicity and ototoxicity. Mechanistically, the released cisplatin enters tumor cells and forms covalent adducts with DNA, primarily intrastrand cross-links, which distort the DNA duplex, inhibit replication and transcription, and activate apoptotic signaling pathways.
- Brand names
- 顺铂缓释微粒
- Other names
- cisplatin
02
Targets
DNA
Beyond the preview
Go deeper on SCP-cisplatin.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on SCP-cisplatin.